At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 48 enrolled
Drug / intervention
CC-93538 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Induction and Maintenance Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Japanese Subjects With Eosinophilic Gastroenteritis
In Brief
A Phase 3 clinical trial evaluating CC-93538 and Placebo for Eosinophilic Gastroenteritis. Completed, enrolled 48 participants across 25 sites.
Detailed Summary
The purpose of this study is to evaluate the safety and efficacy of CC-93538 in adult and adolescent participants with eosinophilic gastroenteritis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEosinophilic Gastroenteritis
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
20222023202420252026
First PostedJan 2022
Enrollment StartMar 2022
Primary CompletionJul 2024
Study CompletionAug 2025
TodayJul 2026
First PostedJan 31, 2022
Enrollment StartMar 4, 2022
Primary CompletionJul 2, 2024
Study CompletionAug 22, 2025
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 4.4 years ago
Interventions
CC-93538drug
Specified dose on specified days
Placebodrug
Specified dose on specified days